MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics. Click here to learn how to join the https://www.ademilaw.com/case/akili-inc or call Guri Ademi toll-free at 866- 264-3995. There is no cost or obligation to you. In the transaction, Akili shareholders will receive only $0.4340 per share of common stock in cash. The transaction agreement unreasonably limits co ...